Micah Chiles

[Targeted Oncology @TargetedOnc]

WATCH: Nicolas Girard, MD, PhD, discusses the final overall survival results from the MARIPOSA trial of amivantamab plus lazertinib in EGFR-mutant advanced #NSCLC. #lcsm #ELCC25 | @myESMO @nicogirardcurie

https://t.co/0bpOz4hyDw

[Stephen V Liu, MD @StephenVLiu]

#ELCC25 program includes OS updates from MARIPOSA & LAURA in #EGFR NSCLC, adagrasib + pembrolizumab in #KRAS G12C, & final analysis from KEYNOTE 799 of pembrolizumab + chemoradiation in stage III NSCLC. Educational program highlights include AI session with Dr. @PrelajArsela

[Joshua Bauml, MD @Jbauml]

Proud to share a topline overall survival announcement from the Phase 3 MARIPOSA trial in EGFR-mutated #NSCLC. These data reinforce @JNJInnovMed’s dedication to help transform what’s possible in cancer care and potentially give patients more time and hope: https://t.co/Ug1aHpoqJP

[Joshua Bauml, MD @Jbauml]

The 5 year survival rate for EGFR-mutated non-small cell lung cancer is less than 20%. [tag] @JNJInnovMed is committed to changing this statistic. Learn about our topline results from the pivotal Phase 3 MARIPOSA study in patients with EGFR-mutated #NSCLC: https://t.co/fqc5ZYkmHO

[Micah Chiles @micahchiles]

@MAWildgust @JanssenGlobal How was it? We live close to their and as a corgi owner, feel terrible we haven’t gone yet